What the Supreme Court’s tariff ruling means for drug imports: 3 notes

Becker’s Hospital Review – Wednesday, February 25, 2026
By: Ella Jeffries

The Supreme Court’s Feb. 20 ruling against President Donald Trump’s use of emergency powers to impose tariffs marked a major legal setback, but it is not a full reprieve for hospital leaders and pharmaceutical manufacturers navigating global supply chains.

In a 6-3 decision, the court blocked the administration’s use of the International Emergency Economic Powers Act to levy sweeping reciprocal duties, including a 34% tariff on Chinese imports and penalties on goods from Canada and Mexico. The ruling curbs the president’s ability to act unilaterally in peacetime under the IEEPA. a statute traditionally used for sanctions and asset freezes during national emergencies. However, it does not affect tariffs enacted under a separate legal authority that remains active: Section 232 of the Trade Expansion Act of 1962.

Click here to read the entire article.